Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025)

InMed Pharmaceuticals (INM) has 4 years of Asset Writedowns and Impairment data on record, last reported at $208737.0 in Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment rose 392.21% year-over-year to $208737.0; the TTM value through Jun 2025 reached $208737.0, down 31.74%, while the annual FY2025 figure was $208737.0, 31.74% down from the prior year.
  • Asset Writedowns and Impairment reached $208737.0 in Q2 2025 per INM's latest filing, up from $42408.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $576772.0 in Q3 2022 and bottomed at -$529997.0 in Q2 2023.
  • Average Asset Writedowns and Impairment over 4 years is $93554.0, with a median of $131702.0 recorded in 2023.
  • Peak YoY movement for Asset Writedowns and Impairment: crashed 83.89% in 2023, then skyrocketed 392.21% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $576772.0 in 2022, then plummeted by 70.44% to $170474.0 in 2023, then tumbled by 75.12% to $42408.0 in 2024, then skyrocketed by 392.21% to $208737.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $208737.0 in Q2 2025, $42408.0 in Q2 2024, and $170474.0 in Q4 2023.